Menu Search
Equities

Lisata Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
8NE:FRA

Lisata Therapeutics Inc

Actions
  • Price (EUR)3.78
  • Today's Change0.04 / 1.07%
  • Shares traded1.00k
  • 1 Year change+54.92%
  • Beta1.2681
Data delayed at least 15 minutes, as of Feb 16 2026 07:14 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.

  • Revenue in USD (TTM)1.07m
  • Net income in USD-18.24m
  • Incorporated1980
  • Employees26.00
  • Location
    Lisata Therapeutics Inc110 Allen Road, Second FloorBASKING RIDGE 07920United StatesUSA
  • Phone+1 (908) 229-2590
  • Fax+1 (845) 818-3588
  • Websitehttps://www.lisata.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.